Rasheeda K Hall1, Jacob B Blumenthal2, Rebecca M Doerfler3, Jing Chen4, Clarissa J Diamantidis5, Bernard G Jaar6, John W Kusek7, Krishna Kallem8, Mary B Leonard9, Sankar D Navaneethan10, Daohang Sha7, James H Sondheimer11, Lee-Ann Wagner3, Wei Yang7, Min Zhan12, Jeffrey C Fink3. 1. Renal Section, Department of Medicine, School of Medicine, Duke University, and Durham Veterans Affairs Healthcare System, Durham, North Carolina. Electronic address: rasheeda.stephens@dm.duke.edu. 2. Division of Gerontology & Geriatric Medicine School of Medicine, University of Maryland, Baltimore, Maryland; Baltimore Geriatrics Research, Department of Medicine, Education and Clinical Center (GRECC), Baltimore Veterans Affairs and Medical Center, Baltimore, Maryland. 3. Department of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland. 4. Department of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana. 5. Renal Section, Department of Medicine, School of Medicine, Duke University, and Durham Veterans Affairs Healthcare System, Durham, North Carolina. 6. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 7. Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 8. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 9. Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California. 10. Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas. 11. Department of Medicine, School of Medicine, Wayne State University, Detroit, Michigan. 12. Department of Epidemiology and Public Health, School of Medicine, University of Maryland, Baltimore, Maryland.
Abstract
RATIONALE & OBJECTIVE: Adults with chronic kidney disease (CKD) may be at increased risk of adverse effects from use of potentially inappropriate medications (PIMs). Our objective was to assess whether PIM exposure has an independent association with CKD progression, hospitalizations, mortality, or falls. STUDY DESIGN: Retrospective observational study. SETTING & PARTICIPANTS: Chronic Renal Insufficiency Cohort (CRIC) study; 3,929 adults with CKD enrolled 2003-2008 and followed prospectively until December 2011. EXPOSURE: PIM exposure was defined as prescriptions for any medications to be avoided in older adults as defined by the 2015 American Geriatrics Society Beers Criteria. OUTCOME: Hospitalization count, death, a composite kidney disease end point of CKD progression or initiation of kidney replacement therapy (KRT), KRT, and fall events assessed 1 year after PIM exposure. ANALYTICAL APPROACH: Logistic regression and Poisson regression to estimate the associations of PIM exposure with each outcome. RESULTS: The most commonly prescribed PIMs were proton pump inhibitors and α-blockers. In unadjusted models, any PIM exposure (compared to none) was associated with hospitalizations, death, and fall events. After adjustment, exposure to 1, 2, or≥3 PIMs had a graded association with a higher hospitalization rate (rate ratios of 1.09 [95% CI, 1.01-1.17], 1.18 [95% CI, 1.07-1.30], and 1.35 [95% CI, 1.19-1.53], respectively) and higher odds of mortality (odds ratios of 1.19 [95% CI, 0.91-1.54], 1.62 [95% CI, 1.21-2.17], and 1.65 [95% CI, 1.14-2.41], respectively). In a cohort subset reporting falls (n=1,109), prescriptions for≥3 PIMs were associated with an increased risk of falls (adjusted OR, 2.85 [95% CI, 1.54-5.26]). PIMs were not associated with CKD progression or KRT. Age did not modify the association between PIM count and outcomes. LIMITATIONS: Measurement bias; confounding by indication. CONCLUSIONS: Adults of any age with CKD who are prescribed PIMs have an increased risk of hospitalization, mortality, and falls with the greatest risk occurring after more than 1 PIM prescription. Published by Elsevier Inc.
RATIONALE & OBJECTIVE: Adults with chronic kidney disease (CKD) may be at increased risk of adverse effects from use of potentially inappropriate medications (PIMs). Our objective was to assess whether PIM exposure has an independent association with CKD progression, hospitalizations, mortality, or falls. STUDY DESIGN: Retrospective observational study. SETTING & PARTICIPANTS: Chronic Renal Insufficiency Cohort (CRIC) study; 3,929 adults with CKD enrolled 2003-2008 and followed prospectively until December 2011. EXPOSURE: PIM exposure was defined as prescriptions for any medications to be avoided in older adults as defined by the 2015 American Geriatrics Society Beers Criteria. OUTCOME: Hospitalization count, death, a composite kidney disease end point of CKD progression or initiation of kidney replacement therapy (KRT), KRT, and fall events assessed 1 year after PIM exposure. ANALYTICAL APPROACH: Logistic regression and Poisson regression to estimate the associations of PIM exposure with each outcome. RESULTS: The most commonly prescribed PIMs were proton pump inhibitors and α-blockers. In unadjusted models, any PIM exposure (compared to none) was associated with hospitalizations, death, and fall events. After adjustment, exposure to 1, 2, or≥3 PIMs had a graded association with a higher hospitalization rate (rate ratios of 1.09 [95% CI, 1.01-1.17], 1.18 [95% CI, 1.07-1.30], and 1.35 [95% CI, 1.19-1.53], respectively) and higher odds of mortality (odds ratios of 1.19 [95% CI, 0.91-1.54], 1.62 [95% CI, 1.21-2.17], and 1.65 [95% CI, 1.14-2.41], respectively). In a cohort subset reporting falls (n=1,109), prescriptions for≥3 PIMs were associated with an increased risk of falls (adjusted OR, 2.85 [95% CI, 1.54-5.26]). PIMs were not associated with CKD progression or KRT. Age did not modify the association between PIM count and outcomes. LIMITATIONS: Measurement bias; confounding by indication. CONCLUSIONS: Adults of any age with CKD who are prescribed PIMs have an increased risk of hospitalization, mortality, and falls with the greatest risk occurring after more than 1 PIM prescription. Published by Elsevier Inc.
Authors: Marcela Jirón; Virginia Pate; Laura C Hanson; Jennifer L Lund; Michele Jonsson Funk; Til Stürmer Journal: J Am Geriatr Soc Date: 2016-04 Impact factor: 5.562
Authors: Jeroen P Kooman; Peter Kotanko; Annemie M W J Schols; Paul G Shiels; Peter Stenvinkel Journal: Nat Rev Nephrol Date: 2014-10-07 Impact factor: 28.314
Authors: Wubshet H Tesfaye; Barbara C Wimmer; Gregory M Peterson; Ronald L Castelino; Matthew D Jose; Charlotte McKercher; Syed Tabish R Zaidi Journal: Curr Med Res Opin Date: 2019-01-11 Impact factor: 2.580
Authors: C Barrett Bowling; John N Booth; Orlando M Gutiérrez; Manjula Kurella Tamura; Lei Huang; Meredith Kilgore; Suzanne Judd; David G Warnock; William M McClellan; Richard M Allman; Paul Muntner Journal: Clin J Am Soc Nephrol Date: 2014-10-02 Impact factor: 8.237
Authors: Min Zhan; Rebecca M Doerfler; Dawei Xie; Jing Chen; Hsiang-Yu Chen; Clarissa J Diamantidis; Mahboob Rahman; Ana C Ricardo; James Sondheimer; Louise Strauss; Lee-Ann Wagner; Matthew R Weir; Jeffrey C Fink Journal: Am J Kidney Dis Date: 2020-04-18 Impact factor: 8.860
Authors: James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237
Authors: Marcus Säemann; Daniel Cejka; Sabine Schmaldienst; Alexander R Rosenkranz; Gert Mayer Journal: Wien Klin Wochenschr Date: 2022-10-17 Impact factor: 2.275
Authors: Joanna Q Hudson; Rebecca Maxson; Erin F Barreto; Katherine Cho; Amanda J Condon; Elizabeth Goswami; Jean Moon; Bruce A Mueller; Thomas D Nolin; Heather Nyman; A Mary Vilay; Calvin J Meaney Journal: Kidney Med Date: 2022-06-25